ZA201900156B - Phosphoramidates for the treatment of hepatitis b virus - Google Patents

Phosphoramidates for the treatment of hepatitis b virus

Info

Publication number
ZA201900156B
ZA201900156B ZA2019/00156A ZA201900156A ZA201900156B ZA 201900156 B ZA201900156 B ZA 201900156B ZA 2019/00156 A ZA2019/00156 A ZA 2019/00156A ZA 201900156 A ZA201900156 A ZA 201900156A ZA 201900156 B ZA201900156 B ZA 201900156B
Authority
ZA
South Africa
Prior art keywords
phosphoramidates
hepatitis
virus
treatment
Prior art date
Application number
ZA2019/00156A
Other languages
English (en)
Inventor
La Rosa Abel De
George Painter
Gregory R Bluemling
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of ZA201900156B publication Critical patent/ZA201900156B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
ZA2019/00156A 2016-06-24 2019-01-09 Phosphoramidates for the treatment of hepatitis b virus ZA201900156B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662354471P 2016-06-24 2016-06-24
PCT/US2017/038963 WO2017223421A1 (en) 2016-06-24 2017-06-23 Phosphoramidates for the treatment of hepatitis b virus

Publications (1)

Publication Number Publication Date
ZA201900156B true ZA201900156B (en) 2019-08-28

Family

ID=60783488

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/00156A ZA201900156B (en) 2016-06-24 2019-01-09 Phosphoramidates for the treatment of hepatitis b virus

Country Status (14)

Country Link
US (2) US11364257B2 (https=)
EP (1) EP3474863A4 (https=)
JP (2) JP2019525905A (https=)
KR (1) KR20190057277A (https=)
CN (1) CN109689065A (https=)
AU (1) AU2017281531A1 (https=)
BR (1) BR112018076913A2 (https=)
CA (1) CA3029315A1 (https=)
EA (1) EA201990059A1 (https=)
IL (1) IL263859B2 (https=)
PH (1) PH12018550207A1 (https=)
SG (1) SG11201811316YA (https=)
WO (1) WO2017223421A1 (https=)
ZA (1) ZA201900156B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202013032YA (en) * 2014-12-15 2021-02-25 Univ Emory Phosphoramidates for the treatment of hepatitis b virus
EP3752511A4 (en) 2018-01-10 2021-12-29 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11628182B2 (en) * 2018-04-12 2023-04-18 Zogenix Mds, Inc. Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools
WO2020045628A1 (ja) * 2018-08-31 2020-03-05 ダイキン工業株式会社 核酸アナログ及び抗ｂ型肝炎ウイルス剤
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2020103929A1 (zh) * 2018-11-23 2020-05-28 正大天晴药业集团股份有限公司 低聚核苷酸及前体药物
CN114206896B (zh) 2019-07-17 2024-12-17 纽科利制药公司 环状脱氧核糖核苷酸化合物
CN110642910B (zh) * 2019-09-02 2020-10-30 南开大学 胸苷衍生物及其制备方法和用途
WO2021067480A1 (en) * 2019-10-02 2021-04-08 University Of Washington Compositions and methods for treatment of hepatitis b virus infection
CN111087421B (zh) * 2019-12-24 2022-10-18 南京正大天晴制药有限公司 一种用于手性药物合成的磷酰胺化合物的制备方法
US12516080B2 (en) 2020-04-02 2026-01-06 The Regents Of The University Of Michigan Remdesivir and remdesivir analogs, solutions, and nanoparticle, liposomal, and microparticle compositions for treating viral infections
CN113493481B (zh) * 2020-04-08 2025-02-18 北京君科华元医药科技有限公司 单磷酸恩替卡韦丙氨酰胺酚酯及其医药用途
US12552820B2 (en) 2020-04-21 2026-02-17 Ligand Pharmaceuticals Incorporated Benzyloxy phosph(on)ate compounds
WO2021253376A1 (zh) * 2020-06-19 2021-12-23 南京正大天晴制药有限公司 一种用于手性药物合成的磷酰胺化合物的制备方法
WO2022251594A1 (en) * 2021-05-27 2022-12-01 Antios Therapeutics, Inc. Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs
WO2022256490A2 (en) * 2021-06-03 2022-12-08 Antios Therapeutics, Inc. Improved synthesis of phosphoramidates for the treatment of hepatitis b virus
CN113501853B (zh) * 2021-09-13 2021-12-07 南京颐媛生物医学研究院有限公司 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途
CA3243401A1 (en) * 2022-01-28 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Polytherapy for the treatment of hepatitis B virus infections
CN115260263B (zh) * 2022-05-23 2025-02-21 浙江扬厉医药技术有限公司 烷基硫芳基克拉夫定磷酰胺类化合物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687931A (en) 1970-03-19 1972-08-29 Syntex Corp Halogenated purine and pyrimidine nucleosides and process therefor
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2589935A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
EA016838B1 (ru) 2005-06-07 2012-07-30 Йельский Университет Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2398684T3 (es) 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
US20120142627A1 (en) * 2010-12-06 2012-06-07 Emory University Monophosphate prodrugs of dapd and analogs thereof
US20140315850A1 (en) 2011-07-19 2014-10-23 Nanjing Molecular Research, Inc. 2',3'-Dideoxy-2'-alpha-Fluoro-2'-beta-C-Methylnucleosides and Prodrugs Thereof
BR112015009636A8 (pt) 2012-10-29 2018-04-17 Cocrystal Pharma Inc composto, métodos para o tratamento de um hospedeiro infectado, métodos para a prevenção de uma infecção, métodos para a redução da atividade biológica de uma infecção e uso de um composto
EP2920195A1 (en) 2012-11-14 2015-09-23 IDENIX Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
AU2014250762A1 (en) * 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
SG10202013032YA (en) * 2014-12-15 2021-02-25 Univ Emory Phosphoramidates for the treatment of hepatitis b virus

Also Published As

Publication number Publication date
KR20190057277A (ko) 2019-05-28
US20190350954A1 (en) 2019-11-21
WO2017223421A1 (en) 2017-12-28
CN109689065A (zh) 2019-04-26
IL263859A (en) 2019-01-31
US20220280542A1 (en) 2022-09-08
EA201990059A1 (ru) 2019-07-31
JP2022116024A (ja) 2022-08-09
US11364257B2 (en) 2022-06-21
SG11201811316YA (en) 2019-01-30
AU2017281531A1 (en) 2019-01-17
PH12018550207A1 (en) 2019-04-15
EP3474863A1 (en) 2019-05-01
IL263859B1 (en) 2023-03-01
JP2019525905A (ja) 2019-09-12
CA3029315A1 (en) 2017-12-28
IL263859B2 (en) 2023-07-01
BR112018076913A2 (pt) 2019-04-02
EP3474863A4 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL295609B1 (en) Hemisulfate nucleotide salt for treatment of hepatitis c virus
IL274040A (en) Methods for treating hepatitis B infection
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
IL246449B (en) Conjugated 6-heteroaryl dihydropyrimidines for the treatment and prevention of hepatitis b virus infection
IL249660A0 (en) Methods for treating hepatitis b virus and hepatitis d virus infections
HUE044606T2 (hu) A hepatitis delta vírusfertõzés kezelése
IL258137A (en) HIV treatment measures
SI3471732T1 (sl) Liposomi za zdravljenje virusnih infekcij
HK40005971A (en) Phosphoramidates for the treatment of hepatitis b virus
GB201600380D0 (en) Modified virus